MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis
Open accessAbstract
Purpose This study compared miRNA expression patterns in primary squamous cell lung carcinoma specimens with those of matched normal lung tissue in order to determine their potential relevance to clinicopathological factors and patient postoperative survival times. Methods Locked nucleic acids miRNA microarray expression profiling was performed on four matched pairs of tissues. After microarray validation by quantitative real-time reverse transcription polymerase chain reaction assays (qRT-PCR) (real-time PCR), miR-21 was selected for further TaqMan real-time PCR study in 30 matched tissue pairs. Results Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold. MiR-21 was overexpressed in 73.3% of the squamous cell lung carcinoma specimens examined (P = 0.022). The relationship between the miR-21 expression level and various clinicopathologic factors was also analyzed. High-level expression of miR-21 was significantly correlated with shortened survival time (P = 0.022, log-rank test; Kaplan-Meier). Multivariate Cox proportional hazard regression analysis revealed this significant prognostic impact (P = 0.000; HR 1.293; 95% CI 1.123-1.489) to be independent of clinical disease stage (P = 0.013; HR 2.660; 95% CI 1.229-5.758) and other clinicopathologic factors. Conclusions Expression patterns of miRNAs were found to be systematically altered in squamous cell lung carcinoma tissue. High miR-21 expression is associated with shortened survival time, indicating that miR-21 may serve as a molecular diagnostic and prognostic marker for patients with squamous cell lung carcinoma.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Population-specific genetic and environmental factors may influence miR-21 expression, leading to variations in diagnostic performance and prognostic utility.
“Addressing this gap is crucial, as population-specific genetic and environmental factors may influence microRNA e.g.miR-21 expression, leading to variations in the diagnostic performance and prognostic utility as well as therapeutic response [14,15].”
From miR-21 as a diagnostic and prognostic biomarker in glioma: tissue and serum expression analysis in a Pakistani cohort (2026) · cites this paper as [15]
The Discussion reports that miR-21 has different diagnostic and prognostic implications across cancer types and suggests that specimen origin or individual patient variation may explain discrepancies in miRNA profiles. It does not identify population-specific genetic or environmental factors as causes of miR-21 expression differences, or show that such factors change diagnostic performance or prognostic utility across populations. Page numbers are not available in our copy. (LLM, conf=0.82)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Meng, F., Henson, R., Lang, M., Wehbe, H., Maheshwari, S., Mendell, J. T., Jiang, J., Schmittgen, T. D., & Patel, T. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.057 · Cited by 984 · see citing works
MicroRNA 21 Promotes Glioma Invasion by Targeting Matrix Metalloproteinase Regulators
Gabriely, G., Wurdinger, T., Kesari, S., Esau, C. C., Burchard, J., Linsley, P. S., & Krichevsky, A. M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00479-08 · Cited by 888 · cited 1× · see citing works
“Regulation of PTEN expression by miR-21 was also identi-Wed in colon cancer (Asangani et al. 2008); however, researchers did not Wnd this regulatory role in breast cancer MCF-7 cells (Frankel et al. 2008), lung adenocarcinoma A549 cells (Blower et al., 2008), or glioma cells ( Gabriely et al. 2008 ).”
Background
Flagged first, then by citations
Research works printed but not linked: 3
- Gao W, Yu Y, Cao HL, Shen H, Li XD, Pan SY, Shu YQ (2010) Deregulated expression of miR-21,miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother (in press, accepted on Jan 29, 2010)
- Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging handbook-TNM classi W cation of malignant tumors, 6th edn. Springer, New York
- Sobin LH, Wittekind C (2002) UICC TNM classi W cation of malignant tumours, 6th edn. Wiley, New York
Cited by
Sorted by citations
Laghari, A. A., Sufiyan, S., Amin, W., Ilyas, S., Naeem, S., Adnan, U., Abidi, S. H., Uddin, S., Enam, S. A., & Mughal, N. (2026) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-05287-4 · Cited by 1 · see citing works
“Addressing this gap is crucial, as population-specific genetic and environmental factors may influence microRNA e.g. miR-21 expression, leading to variations in the diagnostic performance and prognostic utility as well as therapeutic response [14, 15].”
- Authors
- Gao, W., Shen, H., Liu, L., Xu, J., Xu, J., & Shu, Y.
- Affiliations
- Jiangsu Province Hospital (CN)
- Corresponding author
- Shu, Yongqian
- Venue
- Journal of Cancer Research and Clinical Oncology
- Published
- 2010-05-28
- Volume
- 137
- Issue
- 4
- Pages
- 557-566
- ISSN
- 0084-5353 (ISSN-L)
- 0171-5216
- 1432-1335
- PMC
- PMC11828261
- OpenAlex
- W2006535551
- Cited by
- 237
- References
- 2
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 5 · 2023: 11 · 2022: 7 · 2021: 5 · 2020: 11 · 2019: 12 · 2018: 8 · 2017: 16 · 2016: 17 · 2015: 25 · 2014: 36 · 2013: 27 · 2012: 27
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Cancer Research and Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung squamous cell carcinoma, miRNA expression profiling, prognostic factors, postoperative survival, clinicopathological features, miR-31, miR-34a, miR-22, miR-504, miR-18a, miR-30a, miR-126, miR-652, miR-100, miR-143
- MeSH terms
- Carcinoma, Squamous Cell, Humans, Lung Neoplasms, Prognosis, Quality Control, Biomarkers, Tumor, Polymerase Chain Reaction, RNA-Binding Proteins, Oligonucleotide Array Sequence Analysis, MicroRNAs, Apoptosis Regulatory Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review